<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01410214</url>
  </required_header>
  <id_info>
    <org_study_id>C-LCSG-001</org_study_id>
    <nct_id>NCT01410214</nct_id>
  </id_info>
  <brief_title>Erlotinib Versus Vinorelbine/Cisplatin as Adjuvant Treatment in Stage IIIA NSCLC Patients With EGFR Mutations</brief_title>
  <official_title>A Phase II Trial of Erlotinib Versus Combination of Vinorelbine Plus Cisplatin as Adjuvant Treatment in Stage IIIA Non-small-cell Lung Cancer After Complete Resection With Sensitizing EGFR Mutation in Exon 19 or 21 and Wild-type K-ras</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chinese Lung Cancer Surgical Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Tianjin Medical University Cancer Institute and Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fudan University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Zhejiang Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Beijing Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Chinese PLA General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Qingdao University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The First Affiliated Hospital of Soochow University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Harbin Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hebei Medical University Fourth Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Second People's Hospital of Sichuan</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Chinese Lung Cancer Surgical Group</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the effect and safety of erlotinib versus NVB plus
      cisplatin (NP) as adjuvant treatment in patients with stage IIIA NSCLC after complete
      resection with EGFR activating mutations and to explore a new treatment strategy for this
      subset.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The LACE meta-analysis identified four cycles of platinum-based program to improve II~IIIA
      stage completely resected NSCLC pts the role of 5-year survival, but its treatment-related
      life threatening toxicity limits its use. The EGFR tyrosine kinase inhibitor (TKI) may
      provide a dramatic response in pts with pulmonary adenocarcinoma carrying EGFR activating
      mutations in the metastatic setting. The aim of this study is to investigate the efficacy and
      safety of erlotinib versus NVB plus cisplatin (NP) as adjuvant treatment in pts with stage
      IIIA NSCLC after Complete Resection with EGFR activating mutations and to explore a new
      treatment strategy for this subset.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>May 2011</start_date>
  <completion_date type="Anticipated">July 2017</completion_date>
  <primary_completion_date type="Anticipated">July 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Disease-free survival</measure>
    <time_frame>2 years</time_frame>
    <description>To evaluate Disease-free survival(DFS) of two groups</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Adverse Events</measure>
    <time_frame>2 years</time_frame>
    <description>To evaluate the safety profile(Number of Participants with Adverse Events) of two group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life (QOL)</measure>
    <time_frame>2 years</time_frame>
    <description>To evaluate the Quality of Life (QOL) of two group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall survival (OS)</measure>
    <time_frame>2 years</time_frame>
    <description>To evaluate the overall survival (OS) of two groups</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Non-small Cell Lung Cancer Stage IIIA</condition>
  <arm_group>
    <arm_group_label>Erlotinib arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In the adjuvant treatment phase, erlotinib 150 mg/day taken orally for 2 years or till disease progression or unacceptable toxicity.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Chemo arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>In the adjuvant treatment phase, patient will receive vinorelbine 25mg/m2 IV on day 1 and day 8, and cisplatin 25mg/m2 on day 1 and day 2 and day 3, of a 3-week schedule for 4 cycles or till disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Erlotinib</intervention_name>
    <description>In the adjuvant treatment phase, erlotinib 150 mg/day taken orally for 2 years or till disease progression or unacceptable toxicity.</description>
    <arm_group_label>Erlotinib arm</arm_group_label>
    <other_name>tarceva</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vinorelbine/cisplatin</intervention_name>
    <description>In the adjuvant treatment phase, patient will receive vinorelbine 25mg/m2 IV on day 1 and day 8, and cisplatin 25mg/m2 on day 1 and day 2 and day 3, of a 3-week schedule for 4 cycles or till disease progression or unacceptable toxicity.</description>
    <arm_group_label>Chemo arm</arm_group_label>
    <other_name>NP</other_name>
    <other_name>NVB/cisplatin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Written informed consent provided.

          -  Males or females aged ≥18 years.

          -  Chest CT, brain CT or MRI, ECT, abdominal and double-neck B-, or whole body PET-CT
             examination in 4 weeks before complete resection.

          -  Pathological diagnosed of non-small cell lung cancer.

          -  Diagnosed as stage IIIA.

          -  In 4 weeks after complete resection pts start to accept the adjuvant therapy in this
             study, previously did not receive any anti-tumor therapy.

          -  EGFR activating mutation in exon 19 or 21 and KARS

          -  ECOG performance status 0-1.

          -  Life expectancy ≥3 months.

          -  Adequate hematological function:Absolute neutrophil count (ANC) ≥1.5 x 109/L, and
             Platelet count ≥100 x 109/L, and Hemoglobin ≥9 g/dL (may be transfused to maintain or
             exceed this level).

          -  Adequate liver function: Total bilirubin ≤ 1.5 x upper limit of normal (ULN);Aspartate
             aminotransferase (AST), alanine aminotransferase (ALT) ≤ 2.5 x ULN.

          -  Adequate renal function:Serum creatinine ≤ 1.25 x ULN, and creatinine clearance ≥ 60
             ml/min.

          -  Able to comply with the required protocol and follow-up procedures, and able to
             receive oral medications.

          -  Patients must be nonpregnant and non-lactating.Patients of childbearing potential must
             implement an effective method of contraception during the study. All female Patients,
             except those who are postmenopausal or surgically sterilized, must have a negative
             pre-study serum or urine pregnancy test. .

        Exclusion Criteria:

          -  Patients with prior exposure to agents directed at the HER axis (e.g. erlotinib,
             gefitinib, cetuximab, trastuzumab).

          -  Patients with prior chemotherapy or therapy with systemic anti-tumour therapy.

          -  Patients with prior radiotherapy.

          -  History of another malignancy in the last 5 years with the exception of the
             following:Cured basal cell carcinoma of the skin and cured in situ carcinoma of the
             uterine cervix are permitted.

          -  Any evidence confirmed tumor recurrence before adjuvant treatment.

          -  Any unstable systemic disease (including active infection, uncontrolled hypertension,
             unstable angina, congestive heart failure, myocardial infarction within the previous
             year, serious cardiac arrhythmia requiring medication, hepatic, renal, or metabolic
             disease).

          -  Any evidence of clinically active interstitial lung disease.

          -  Eye inflammation or eye infection not fully treated or conditions predisposing the
             subject to this.

          -  Known human immunodeficiency virus (HIV) infection.

          -  Known hypersensitivity to Tarceva or NVB or cisplatin.

          -  Pregnancy or breast-feeding women.

          -  ECOG performance status ≥ 2.

          -  Ingredients mixed with small cell lung cancer patients

          -  Evidence of any other disease, neurological or metabolic dysfunction, physical
             examination or laboratory finding giving reasonable suspicion of a disease or
             condition that contraindicated the use of an investigational drug or puts the subject
             at high risk for treatment-related complications.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Changli Wang</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tianjin Medical University Cancer Institute and Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xuefeng Kan</last_name>
    <email>13920870123@126.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Beijing Cancer Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chao Lv</last_name>
    </contact>
    <investigator>
      <last_name>Yue Yang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chinese PLA General Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Tao Wang</last_name>
    </contact>
    <investigator>
      <last_name>Xiangyang Chu</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sun Yat-Sen University Cancer Center</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lanjun Zhang</last_name>
    </contact>
    <investigator>
      <last_name>Lanjun Zhang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hebei Medical University Fourth Hospital</name>
      <address>
        <city>Shijiazhuang</city>
        <state>Hebei</state>
        <zip>050000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xinbo Liu</last_name>
    </contact>
    <investigator>
      <last_name>Junfeng Liu</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Harbin Medical University Cancer Hospital</name>
      <address>
        <city>Harbin</city>
        <state>Heilongjiang</state>
        <zip>150000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Changfa Qu</last_name>
    </contact>
    <investigator>
      <last_name>Shidong Xu</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The First Affiurted Hospital of Soochow University</name>
      <address>
        <city>Suzhou</city>
        <state>Jiangsu</state>
        <zip>215000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Haitao Ma</last_name>
    </contact>
    <investigator>
      <last_name>Haitao Ma</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Qingdao University Medical College</name>
      <address>
        <city>Qingdao</city>
        <state>Shandong</state>
        <zip>266000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Yongjie Wang</last_name>
    </contact>
    <investigator>
      <last_name>Yi Shen</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fudan University Shanghai Cancer Center</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Yihua Sun</last_name>
    </contact>
    <investigator>
      <last_name>Haiquan Chen</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Second People's Hospital of Sichuan</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuang</state>
        <zip>610000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Qiang Li</last_name>
    </contact>
    <investigator>
      <last_name>Qiang Li</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tianjin Medical University Cancer Institute and Hospital</name>
      <address>
        <city>Tianji</city>
        <state>Tianji</state>
        <zip>300000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xuefeng Kan</last_name>
    </contact>
    <investigator>
      <last_name>Changli Wang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Zhejiang Cancer Hospital</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Xinming Zhou</last_name>
    </contact>
    <investigator>
      <last_name>Weimin Mao</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>December 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 1, 2011</study_first_submitted>
  <study_first_submitted_qc>August 4, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 5, 2011</study_first_posted>
  <last_update_submitted>December 21, 2011</last_update_submitted>
  <last_update_submitted_qc>December 21, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 23, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>NSCLC</keyword>
  <keyword>EGFR Mutation Positive</keyword>
  <keyword>complete resection</keyword>
  <keyword>Erlotinib Versus NVB/Cisplatin as Adjuvant treatment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vinorelbine</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Erlotinib Hydrochloride</mesh_term>
    <mesh_term>Vinblastine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

